Elicio Therapeutics Inc. is a clinical-stage biotechnology company developing lymph node-targeted immunotherapies for the treatment of cancer. The company's proprietary Amphiphile platform delivers immunotherapeutics directly to lymph nodes, the brain center of the immune system, to enhance the activation and amplification of cancer-fighting T cells. Elicio's lead product candidate, ELI-002, is an off-the-shelf therapeutic cancer vaccine targeting the most common KRAS mutations, which drive approximately 25% of all solid tumors. ELI-002 is currently being evaluated in Phase II clinical trials for patients with mutant KRAS-driven pancreatic cancer. The company's pipeline also includes ELI-007, designed for BRAF-driven cancers, and ELI-008, targeting p53 mutations, both in preclinical development. By focusing on lymph node engagement and site-specific antigen delivery, Elicio aims to generate durable immune responses with greater magnitude and persistence compared to conventional immunotherapy approaches, addressing some of the most prevalent and difficult-to-treat solid tumors.